Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 8, 2010, Pages 509-513

  Liu, X W ^a   Li, D M ^a   Xu, G S ^a   Sun, S R ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunoglobulin A nephropathy; Leflunomide; Mycophenolate mofetil; Therapy

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; IMMUNOGLOBULIN A; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY EXCRETION;

EID: 77955705650     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48509     Document Type: Article

References (15)

1. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76: 534-545.
2. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002; 347: 738-748.
3. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001; 60: 1131-1140.
4. Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol. 2005; 32: 1620-1631.
5. Kremer JM, Cannon GW. Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol. 2004; 22: 95-100.
6. Li J, Yao HW, Jin Y, Zhang YF, Li CY, Li YH, Xu SY. Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin. 2002; 23: 551-555.
7. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999; 162: 2095-2102.
8. Philibert D, Cattran D, Cook T. Clinicopathologic correlation in IgA nephropathy. Semin Nephrol. 2008; 28: 10-17.
9. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002; 41: 421-430.
10. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996; 61: 635-642. (Pubitemid 26073611)
11. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004; 13: 601-604.
12. Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis. 2006; 65: 417-418.
13. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008; 17: 638-644.
14. Xu G, Tu W, Jiang D, Xu C. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol. 2009; 29: 362-367.
15. Zhang FS, Nie YK, Jin XM, Yu HM, Li YN, Sun Y. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int. 2009; 29: 1331-1335.